Infantile hemangiomas: An update

American Journal of Clinical Dermatology

Volumn 14, Issue 2, 2013, Pages 111-123

  Kwon, Eun Kyung Mary ^a   Seefeldt, Marcia ^a   Drolet, Beth A ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACEBUTOLOL; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ATENOLOL; COTRIMOXAZOLE; METHYLPREDNISOLONE; PREDNISOLONE; PREDNISONE; PROPRANOLOL; TIMOLOL; TRIAMCINOLONE ACETONIDE; VINCRISTINE;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADRENAL DISEASE; AIRWAY OBSTRUCTION; AMBLYOPIA; ANEMIA; ANGIOMA; ASTIGMATISM; BLEEDING; BLINDNESS; BRADYCARDIA; BRAIN ISCHEMIA; BRONCHOSPASM; BRONCHUS HYPERREACTIVITY; CAPILLARY HEMANGIOMA; CEREBRAL PALSY; CEREBROVASCULAR ACCIDENT; CLINICAL FEATURE; CONGESTIVE HEART FAILURE; CONSTIPATION; CUSHINGOID SYNDROME; DEFORMITY; DEPRESSION; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; EXOPHTHALMOS; FEEDING DISORDER; FEVER; HEART OUTPUT; HEMANGIOENDOTHELIOMA; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOGLYCEMIA; HYPOPIGMENTATION; HYPOTENSION; HYPOTHYROIDISM; HYPOXIA; INFECTION; IRRITABILITY; JAW PAIN; KASABACH MERRITT SYNDROME; KERATOPATHY; LEUKOPENIA; LIVER HEMANGIOMA; LUNG DISEASE; MALAISE; MENTAL DISEASE; MOOD DISORDER; NAUSEA; NEUROMUSCULAR DISEASE; NEUROTOXICITY; NEUTROPENIA; NIGHTMARE; OPTIC NERVE DISEASE; PAIN; PARALYTIC ILEUS; PERIPHERAL NEUROPATHY; PERSONALITY DISORDER; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULSED DYE LASER; RESPIRATORY FAILURE; REVIEW; SCAR FORMATION; SEIZURE; SIDE EFFECT; SKIN ATROPHY; SLEEP; SLEEP DISORDER; STOMACH DISEASE; STRABISMUS; ULCER; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

ADRENAL CORTEX HORMONES; BIOPSY, NEEDLE; COMBINED MODALITY THERAPY; DERMATOLOGIC SURGICAL PROCEDURES; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEMANGIOMA; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; INTERFERON-ALPHA; LASER THERAPY, LOW-LEVEL; MALE; PROPRANOLOL; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SKIN NEOPLASMS; TREATMENT OUTCOME; VINCRISTINE;

EID: 84879539406     PISSN: 11750561     EISSN: 11791888     Source Type: Journal    
DOI: 10.1007/s40257-013-0008-x     Document Type: Review

References (142)

1. Kilcline C, Frieden IJ. Infantile hemangiomas: how common are they? A systematic review of the medical literature. Pediatr Dermatol. 2008;25(2):168-73.
2. Haggstrom AN, Drolet BA, Baselga E, et al. Prospective study of infantile hemangiomas: demographic, prenatal, and perinatal characteristics. J Pediatr. 2007;150(3):291-4.
3. Drolet BA, Esterly NB, Frieden IJ. Hemangiomas in children. New Engl J Med. 1999;341(3):173-81.
4. Drolet BA, Swanson EA, Frieden IJ. Infantile hemangiomas: an emerging health issue linked to an increased rate of low birth weight infants. J Pediatr. 2008;153(5):712-5, 715.e1.
5. Haggstrom AN, Lammer EJ, Schneider RA, et al. Patterns of infantile hemangiomas: new clues to hemangioma pathogenesis and embryonic facial development. Pediatrics. 2006;117(3):698-703.
6. Chiller KG, Passaro D, Frieden IJ. Hemangiomas of infancy: clinical characteristics, morphologic subtypes, and their relationship to race, ethnicity, and sex. Arch Dermatol. 2002;138(12):1567-76.
7. Haggstrom AN, Drolet BA, Baselga E, et al. Prospective study of infantile hemangiomas: clinical characteristics predicting complications and treatment. Pediatrics. 2006;118(3):882-7.
8. Chang LC, Haggstrom AN, Drolet BA, et al. Growth characteristics of infantile hemangiomas: implications for management. Pediatrics. 2008;122(2):360-7.
9. Garzon MC. Infantile hemangiomas. In: Bolognia JL, et al., editors. Dermatology. Spain. 2008;1574-5.
10. North PE, Waner M, Mizeracki A, et al. GLUT1: a newly discovered immunohistochemical marker for juvenile hemangiomas. Hum Pathol. 2000;31(1):11-22.
11. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407(6801):249-57.
12. Nguyen VA, Furhapter C, Romani N, et al. Infantile hemangioma is a proliferation of beta 4-negative endothelial cells adjacent to HLA-DR-positive cells with dendritic cell morphology. Hum Pathol. 2004;35(6):739-44.
13. Bischoff J. Monoclonal expansion of endothelial cells in hemangioma: an intrinsic defect with extrinsic consequences? Trends Cardiovasc Med. 2002;12(5):220-4.
14. Boye E, Yu Y, Paranya G, et al. Clonality and altered behavior of endothelial cells from hemangiomas. J Clin Invest. 2001;107(6):745-52.
15. Walter JW, North PE, Waner M, et al. Somatic mutation of vascular endothelial growth factor receptors in juvenile hemangioma. Genes Chromosomes Cancer. 2002;33(3):295-303.
16. Yu Y, Flint AF, Mulliken JB, et al. Endothelial progenitor cells in infantile hemangioma. Blood. 2004;103(4):1373-5.
17. Kleinman ME, Blei F, Gurtner GC. Circulating endothelial progenitor cells and vascular anomalies. Lymphat Res Biol. 2005;3(4):234-9.
18. Khan ZA, Boscolo E, Picard A, et al. Multipotential stem cells recapitulate human infantile hemangioma in immunodeficient mice. J Clin Invest. 2008;118(7):2592-9.
19. Kleinman ME, Tepper OM, Capla JM, et al. Increased circulating AC133+ CD34+ endothelial progenitor cells in children with hemangioma. Lymphat Res Biol. 2003;1(4):301-7.
20. Greenberger S, Yuan S, Walsh LA, et al. Rapamycin suppresses self-renewal and vasculogenic potential of stem cells isolated from infantile hemangioma. J Invest Dermatol. 2011;131(12):2467-76.
21. Leon-Villapalos J, Wolfe K, Kangesu L. GLUT-1: an extra diagnostic tool to differentiate between haemangiomas and vascular malformations. Br J Plast Surg. 2005;58(3):348-52.
22. North PE, Waner M, Mizeracki A, et al. A unique microvascular phenotype shared by juvenile hemangiomas and human placenta. Arch Dermatol. 2001;137(5):559-70.
23. Itinteang T, Tan ST, Guthrie S, et al. A placental chorionic villous mesenchymal core cellular origin for infantile haemangioma. J Clin Pathol. 2011;64(10):870-4.
24. Bree AF, Siegfried E, Sotelo-Avila C, et al. Infantile hemangiomas: speculation on placental trophoblastic origin. Arch Dermatol. 2001;137(5):573-7.
25. Mihm MC Jr, Nelson JS. Hypothesis: the metastatic niche theory can elucidate infantile hemangioma development. J Cutan Pathol. 2010;37(Suppl. 1):83-7.
26. Drolet BA, Frieden IJ. Characteristics of infantile hemangiomas as clues to pathogenesis: does hypoxia connect the dots? Arch Dermatol. 2010;146(11):1295-9.
27. Blei F, Walter J, Orlow SJ, et al. Familial segregation of hemangiomas and vascular malformations as an autosomal dominant trait. Arch Dermatol. 1998;134(6):718-22.
28. Walter JW, Blei F, Anderson JL, et al. Genetic mapping of a novel familial form of infantile hemangioma. Am J Med Genet. 1999;82(1):77-83.
29. Jinnin M, Medici D, Park L, et al. Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangioma. Nature Med. 2008;14(11):1236-46.
30. Chamlin SL, Haggstrom AN, Drolet BA, et al. Multicenter prospective study of ulcerated hemangiomas. J Pediatr. 2007;151(6):684-9, 9.e1.
31. Maguiness SM, Hoffman WY, McCalmont TH, et al. Early white discoloration of infantile hemangioma: a sign of impending ulceration. Arch Dermatol. 2010;146(11):1235-9.
32. Morelli JG, Tan OT, Yohn JJ, et al. Treatment of ulcerated hemangiomas in infancy. Arch Pediatr Adolesc Med. 1994;148(10):1104-5.
33. Thomas RF, Hornung RL, Manning SC, et al. Hemangiomas of infancy: treatment of ulceration in the head and neck. Arch Facial Plast Surg. 2005;7(5):312-5.
34. Waner M, Suen JY. Hemangiomas and vascular malformations of the head and neck. New York: Wiley-Liss; 1999.
35. Ceisler EJ, Santos L, Blei F. Periocular hemangiomas: what every physician should know. Pediatr Dermatol. 2004;21(1):1-9.
36. Metry DW. Epidemiology; pathogenesis; clinical features; and complications of infantile hemangiomas. In: UpToDate, Basow, DS, editor. Waltham: UpToDate; 2012.
37. Frieden IJ, Haggstrom AN, Drolet BA, et al. Infantile hemangiomas: current knowledge, future directions. Proceedings of a research workshop on infantile hemangiomas, April 7-9, 2005, Bethesda, Maryland, USA. Pediatr Dermatol. 2005;22(5):383-406.
38. Shikhani AH, Jones MM, Marsh BR, et al. Infantile subglottic hemangiomas: an update. Ann Otol Rhinol Laryngol. 1986;95(4 Pt 1):336-47.
39. Bitar MA, Moukarbel RV, Zalzal GH. Management of congenital subglottic hemangioma: trends and success over the past 17 years. Otolaryngol Head Neck Surg. 2005;132(2):226-31.
40. Orlow SJ, Isakoff MS, Blei F. Increased risk of symptomatic hemangiomas of the airway in association with cutaneous hemangiomas in a "beard" distribution. J Pediatr. 1997;131(4):643-6.
41. Haggstrom AN, Skillman S, Garzon MC, et al. Clinical spectrum and risk of PHACE syndrome in cutaneous and airway hemangiomas. Arch Otolaryngol Head Neck Surg. 2011;137(7):680-7.
42. Rahbar R, Nicollas R, Roger G, et al. The biology and management of subglottic hemangioma: past, present, future. Laryngoscope. 2004;114(11):1880- 91.
43. Lopriore E, Markhorst DG. Diffuse neonatal haemangiomatosis: new views on diagnostic criteria and prognosis. Acta Paediatr. 1999;88(1):93-7.
44. Boon LM, Burrows PE, Paltiel HJ, et al. Hepatic vascular anomalies in infancy: a twenty-seven-year experience. J Pediatr. 1996;129(3):346-54.
45. Dickie B, Dasgupta R, Nair R, et al. Spectrum of hepatic hemangiomas: management and outcome. J Pediatr Surg. 2009;44(1):125-33.
46. Horii KA, Drolet BA, Baselga E, et al. Risk of hepatic hemangiomas in infants with large hemangiomas. Arch Dermatol. 2010;146(2):201-3.
47. Drolet BA, Pope E, Juern AM, et al. Gastrointestinal bleeding in infantile hemangioma: a complication of segmental, rather than multifocal, infantile hemangiomas. J Pediatr. 2012;160(6):1021-6.e3.
48. Christison-Lagay ER, Burrows PE, Alomari A, et al. Hepatic hemangiomas: subtype classification and development of a clinical practice algorithm and registry. J Pediatr Surg. 2007;42(1):62-7. discussion 7-8.
49. Huang SA, Tu HM, Harney JW, et al. Severe hypothyroidism caused by type 3 iodothyronine deiodinase in infantile hemangiomas. N Engl J Med. 2000;343(3):185-9.
50. Bessho K, Etani Y, Ichimori H, et al. Increased type 3 iodothyronine deiodinase activity in a regrown hepatic hemangioma with consumptive hypothyroidism. Eur J Pediatr. 2010;169(2):215-21.
51. Konrad D, Ellis G, Perlman K. Spontaneous regression of severe acquired infantile hypothyroidism associated with multiple liver hemangiomas. Pediatrics. 2003;112(6):1424-6.
52. Imteyaz H, Karnsakul W, Levine MA, et al. An unusual case of hypothyroidism in an infant with hepatic hemangioma. J Pediatr Gastroenterol Nutr. 2012;54(5):692-5.
53. Frieden IJ, Reese V, Cohen D. PHACE syndrome: the association of posterior fossa brain malformations, hemangiomas, arterial anomalies, coarctation of the aorta and cardiac defects, and eye abnormalities. Arch Dermatol. 1996;132(3):307-11.
54. Metry D, Heyer G, Hess C, et al. Consensus statement on diagnostic criteria for PHACE syndrome. Pediatrics. 2009;124(5):1447-56.
55. Metry DW, Garzon MC, Drolet BA, et al. PHACE syndrome: current knowledge, future directions. Pediatr Dermatol. 2009;26(4):381-98.
56. Siegel DH, Tefft KA, Kelly T, et al. Stroke in children with posterior fossa brain malformations, hemangiomas, arterial anomalies, coarctation of the aorta and cardiac defects, and eye abnormalities (PHACE) syndrome: a systematic review of the literature. Stroke. 2012;43(6):1672-4.
57. Girard C, Bigorre M, Guillot B, et al. PELVIS syndrome. Arch Dermatol. 2006;142(7):884-8.
58. Stockman A, Boralevi F, Taieb A, et al. SACRAL syndrome: spinal dysraphism, anogenital, cutaneous, renal and urologic anomalies, associated with an angioma of lumbosacral localization. Dermatology. 2007;214(1):40-5.
59. Iacobas I, Burrows PE, Frieden IJ, et al. LUMBAR: association between cutaneous infantile hemangiomas of the lower body and regional congenital anomalies. J Pediatr. 2010;157(5):795-801.
60. Drolet BA, Chamlin SL, Garzon MC, et al. Prospective study of spinal anomalies in children with infantile hemangiomas of the lumbosacral skin. J Pediatr. 2010;157(5):789-94.
61. Berk DR, Berk EJ, Bruckner AL. A novel method for calculating the volume of hemangiomas. Pediatr Dermatol. 2011;28(4):478-82.
62. Haggstrom AN, Beaumont JL, Lai JS, et al. Measuring the severity of infantile hemangiomas instrument development and reliability. Arch Dermatol. 2012;148(2):197-202.
63. Dixon JJ, James D, Fleming PJ, et al. A novel method for estimating the volume of capillary haemangioma to determine response to treatment. Clin Exp Dermatol. 1997;22(1):20-2.
64. Tsang MW, Garzon MC, Frieden IJ. How to measure a growing hemangioma and assess response to therapy. Pediatr Dermatol. 2006;23(2):187-90.
65. Leaute-Labreze C, Dumas de la Roque E, Hubiche T, et al. Propranolol for severe hemangiomas of infancy. New Engl J Med. 2008;358(24):2649-51.
66. Pope E, Krafchik BR, Macarthur C, et al. Oral versus high-dose pulse corticosteroids for problematic infantile hemangiomas: a randomized, controlled trial. Pediatrics. 2007;119(6):e1239-47.
67. Zarem HA, Edgerton MT. Induced resolution of cavernous hemangiomas following prednisolone therapy. Plast Reconstr Surg. 1967;39(1):76-83.
68. Fost NC, Esterly NB. Successful treatment of juvenile hemangiomas with prednisone. J Pediatr. 1968;72(3):351-7.
69. US National Institutes of Health. ClinicalTrials.gov [online]. http://www.clinicaltrials.gov. Accessed 2011 Dec 22.
70. Leonardi-Bee J, Batta K, O'Brien C, et al. Interventions for infantile haemangiomas (strawberry birthmarks) of the skin. Cochrane Database Syst Rev. 2011;(5):CD006545.
71. Bennett ML, Fleischer AB Jr, Chamlin SL, et al. Oral corticosteroid use is effective for cutaneous hemangiomas: an evidence-based evaluation. Arch Dermatol. 2001;137(9):1208-13.
72. Enjolras O, Riche MC, Merland JJ, et al. Management of alarming hemangiomas in infancy: a review of 25 cases. Pediatrics. 1990;85(4):491-8.
73. Dinehart SM, Kincannon J, Geronemus R. Hemangiomas: evaluation and treatment. Dermatol Surg. 2001;27(5):475-85.
74. Mulliken JB, Fishman SJ, Burrows PE. Vascular anomalies. Curr Prob Surg. 2000;37(8):521-84.
75. Metry DW, Hebert AA. Benign cutaneous vascular tumors of infancy: when to worry, what to do. Arch Dermatol. 2000;136(7):905-14.
76. Boon LM, MacDonald DM, Mulliken JB. Complications of systemic corticosteroid therapy for problematic hemangioma. Plast Reconstr Surg. 1999;104(6):1616-23.
77. Lomenick JP, Backeljauw PF, Lucky AW. Growth, bone mineral accretion, and adrenal function in glucocorticoid-treated infants with hemangiomas: a retrospective study. Pediatr Dermatol. 2006;23(2):169-74.
78. George ME, Sharma V, Jacobson J, et al. Adverse effects of systemic glucocorticosteroid therapy in infants with hemangiomas. Arch Dermatol. 2004;140(8):963-9.
79. Maronn ML, Corden T, Drolet BA. Pneumocystis carinii pneumonia in infant treated with oral steroids for hemangioma. Arch Dermatol. 2007;143(9):1224-5.
80. Kelly ME, Juern AM, Grossman WJ, et al. Immunosuppressive effects in infants treated with corticosteroids for infantile hemangiomas. Arch Dermatol. 2010;146(7):767-74.
81. Sloan GM, Reinisch JF, Nichter LS, et al. Intralesional corticosteroid therapy for infantile hemangiomas. Plast Reconstr Surg. 1989;83(3):459-67.
82. Chowdri NA, Darzi MA, Fazili Z, et al. Intralesional corticosteroid therapy for childhood cutaneous hemangiomas. Ann Plast Surg. 1994;33(1):46-51.
83. Shorr N, Seiff SR. Central retinal artery occlusion associated with periocular corticosteroid injection for juvenile hemangioma. Ophthalmic Surg. 1986;17(4):229-31.
84. Sutula FC, Glover AT. Eyelid necrosis following intralesional corticosteroid injection for capillary hemangioma. Ophthalmic Surg. 1987;18(2):103-5.
85. Weiss AH. Adrenal suppression after corticosteroid injection of periocular hemangiomas. Am J Ophthalmol. 1989;107(5):518-22.
86. Greenberger S, Boscolo E, Adini I, et al. Corticosteroid suppression of VEGF-A in infantile hemangioma-derived stem cells. New Engl J Med. 2010;362(11):1005-13.
87. Sans V, de la Roque ED, Berge J, et al. Propranolol for severe infantile hemangiomas: follow-up report. Pediatrics. 2009;124(3):e423-31.
88. Buckmiller L, Dyamenahalli U, Richter GT. Propranolol for airway hemangiomas: case report of novel treatment. Laryngoscope. 2009;119(10):2051-4.
89. Denoyelle F, Leboulanger N, Enjolras O, et al. Role of propranolol in the therapeutic strategy of infantile laryngotracheal hemangioma. Int J Pediatr Otorhinolaryngol. 2009;73(8):1168-72.
90. Theletsane T, Redfern A, Raynham O, et al. Life-threatening infantile haemangioma: a dramatic response to propranolol. J Eur Acad Dermatol Venereol. 2009;23(12):1465-6.
91. Zvulunov A, McCuaig C, Frieden IJ, et al. Oral propranolol therapy for infantile hemangiomas beyond the proliferation phase: a multicenter retrospective study. Pediatr Dermatol. 2011;28(2):94-8.
92. Schupp CJ, Kleber JB, Gunther P, et al. Propranolol therapy in 55 infants with infantile hemangioma: dosage, duration, adverse effects, and outcome. Pediatr Dermatol. 2011;28(6):640-4.
93. Missoi TG, Lueder GT, Gilbertson K, et al. Oral propranolol for treatment of periocular infantile hemangiomas. Arch Ophthalmol. 2011;129(7):899-903.
94. Hermans DJ, van Beynum IM, Schultze Kool LJ, et al. Propranolol, a very promising treatment for ulceration in infantile hemangiomas: a study of 20 cases with matched historical controls. J Am Acad Dermatol. 2011;64(5):833-8.
95. Mhanna A, Franklin WH, Mancini AJ. Hepatic infantile hemangiomas treated with oral propranolol: a case series. Pediatr Dermatol. 2011;28(1):39-45.
96. Rosbe KW, Suh KY, Meyer AK, et al. Propranolol in the management of airway infantile hemangiomas. Arch Otolaryngol Head Neck Surg. 2010;136(7):658-65.
97. Bertrand J, McCuaig C, Dubois J, et al. Propranolol versus prednisone in the treatment of infantile hemangiomas: a retrospective comparative study. Pediatr Dermatol. 2011;28(6):649-54.
98. Hogeling M, Adams S, Wargon O. A randomized controlled trial of propranolol for infantile hemangiomas. Pediatrics. 2011;128(2):e259-66.
99. Bagazgoitia L, Hernandez-Martin A, Torrelo A. Recurrence of infantile hemangiomas treated with propranolol. Pediatr Dermatol. 2011;28(6):658-62.
100. Pickoff AS, Zies L, Ferrer PL, et al. High-dose propranolol therapy in the management of supraventricular tachycardia. J Pediatr. 1979;94(1):144-6.
101. Shaddy RE, Boucek MM, Hsu DT, et al. Carvedilol for children and adolescents with heart failure: a randomized controlled trial. JAMA. 2007;298(10):1171-9.
102. Gillette P, Garson A Jr, Eterovic E, et al. Oral propranolol treatment in infants and children. J Pediatr. 1978;92(1):141-4.
103. de Graaf M, Breur JM, Raphael MF, et al. Adverse effects of propranolol when used in the treatment of hemangiomas: a case series of 28 infants. J Am Acad Dermatol. 2011;65(2):320-7.
104. Holland KE, Frieden IJ, Frommelt PC, et al. Hypoglycemia in children taking propranolol for the treatment of infantile hemangioma. Arch Dermatol. 2010;146(7):775-8.
105. Breur JM, de Graaf M, Breugem CC, et al. Hypoglycemia as a result of propranolol during treatment of infantile hemangioma: a case report. Pediatr Dermatol. 2011;28(2):169-71.
106. Pavlakovic H, Kietz S, Lauerer P, et al. Hyperkalemia complicating propranolol treatment of an infantile hemangioma. Pediatrics. 2010;126(6):e1589-93.
107. Manunza F, Syed S, Laguda B, et al. Propranolol for complicated infantile haemangiomas: a case series of 30 infants. Br J Dermatol. 2010;162(2):466-8.
108. Solomon T, Ninnis J, Deming D, et al. Use of propranolol for treatment of hemangiomas in PHACE syndrome. J Perinatol. 2011;31(11):739-41.
109. Marsciani A, Pericoli R, Alaggio R, et al. Massive response of severe infantile hepatic hemangioma to propanolol [letter]. Pediatr Blood Cancer. 2010;54(1):176.
110. Sarialioglu F, Erbay A, Demir S. Response of infantile hepatic hemangioma to propranolol resistant to high-dose methylprednisolone and interferon-alpha therapy. Pediatr Blood Cancer. 2010;55(7):1433-4.
111. Muthamilselvan S, Vinoth PN, Vilvanathan V, et al. Hepatic haemangioma of infancy: role of propranolol. Ann Trop Paediatr. 2010;30(4):335-8.
112. Mazereeuw-Hautier J, Hoeger PH, Benlahrech S, et al. Efficacy of propranolol in hepatic infantile hemangiomas with diffuse neonatal hemangiomatosis. J Pediatr. 2010;157(2):340-2.
113. Sciveres M, Marrone G, Pipitone S, et al. Successful first-line treatment with propranolol of multifocal infantile hepatic hemangioma with high-flow cardiac overload. J Pediatr Gastroenterol Nutr. 2011;53(6):693-5.
114. Bigorre M, Van Kien AK, Valette H. Beta-blocking agent for treatment of infantile hemangioma. Plast Reconstr Surg. 2009;123(6):195e-6e.
115. Blanchet C, Nicollas R, Bigorre M, et al. Management of infantile subglottic hemangioma: acebutolol or propranolol? Int J Pediatr Otorhinolaryngol. 2010;74(8):959-61.
116. Fuchsmann C, Quintal MC, Giguere C, et al. Propranolol as first-line treatment of head and neck hemangiomas. Arch Otolaryngol Head Neck Surg. 2011;137(5):471-8.
117. Raphael MF, de Graaf M, Breugem CC, et al. Atenolol: a promising alternative to propranolol for the treatment of hemangiomas. J Am Acad Dermatol. 2011;65(2):420-1.
118. Guo S, Ni N. Topical treatment for capillary hemangioma of the eyelid using beta-blocker solution. Arch Ophthalmol. 2010;128(2):255-6.
119. Ni N, Langer P, Wagner R, et al. Topical timolol for periocular hemangioma: report of further study. Arch Ophthalmol. 2011;129(3):377-9.
120. Chakkittakandiyil A, Phillips R, Frieden IJ, et al. Timolol maleate 0.5% or 0.1% gel-forming solution for infantile hemangiomas: a retrospective, multicenter, cohort study. Pediatr Dermatol. 2012;29(1):28-31.
121. Kunzi-Rapp K. Topical propranolol therapy for infantile hemangiomas. Pediatr Dermatol. 2012;29(3):154-9.
122. Zimmerman TJ, Kooner KS, Morgan KS. Safety and efficacy of timolol in pediatric glaucoma. Surv Ophthalmol. 1983;28(Suppl.):262-4.
123. Hoskins HD Jr, Hetherington J Jr, Magee SD, et al. Clinical experience with timolol in childhood glaucoma. Arch Ophthalmol. 1985;103(8):1163-5.
124. US National Institutes of Health. ClinicalTrials.gov [online]. http://www.clinicaltrials.gov. Accessed 2012 Jan 23.
125. Storch CH, Hoeger PH. Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action. Br J Dermatol. 2010;163(2):269-74.
126. Itinteang T, Brasch HD, Tan ST, et al. Expression of components of the renin-angiotensin system in proliferating infantile haemangioma may account for the propranolol-induced accelerated involution. J Plast Reconstr Aesthet Surg. 2011;64(6):759-65.
127. Perez Payarols J, Pardo Masferrer J, Gomez Bellvert C. Treatment of life-threatening infantile hemangiomas with vincristine [letter]. N Engl J Med. 1995;333(1):69.
128. Fawcett SL, Grant I, Hall PN, et al. Vincristine as a treatment for a large haemangioma threatening vital functions. Br J Plast Surg. 2004;57(2):168-71.
129. Schirner M, Hoffmann J, Menrad A, et al. Antiangiogenic chemotherapeutic agents: characterization in comparison to their tumor growth inhibition in human renal cell carcinoma models. Clin Cancer Res. 1998;4(5):1331-6.
130. Kung AL, Zetterberg A, Sherwood SW, et al. Cytotoxic effects of cell cycle phase specific agents: result of cell cycle perturbation. Cancer Res. 1990;50(22):7307-17.
131. Ezekowitz RA, Mulliken JB, Folkman J. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. New Engl J Med. 1992;326(22):1456-63.
132. Jimenez-Hernandez E, Duenas-Gonzalez MT, Quintero-Curiel JL, et al. Treatment with interferon-alpha-2b in children with life-threatening hemangiomas. Dermatol Surg. 2008;34(5):640-7.
133. Barlow CF, Priebe CJ, Mulliken JB, et al. Spastic diplegia as a complication of interferon Alfa-2a treatment of hemangiomas of infancy. J Pediatr. 1998;132(3 Pt 1):527-30.
134. Worle H, Maass E, Kohler B, et al. Interferon alpha-2a therapy in haemangiomas of infancy: spastic diplegia as a severe complication. Eur J Pediatr. 1999;158(4):344.
135. Michaud AP, Bauman NM, Burke DK, et al. Spastic diplegia and other motor disturbances in infants receiving interferon-alpha. Laryngoscope. 2004;114(7):1231-6.
136. Heyns AD, Eldor A, Vlodavsky I, et al. The antiproliferative effect of interferon and the mitogenic activity of growth factors are independent cell cycle events: studies with vascular smooth muscle cells and endothelial cells. Exp Cell Res. 1985;161(2):297-306.
137. Stier MF, Glick SA, Hirsch RJ. Laser treatment of pediatric vascular lesions: port wine stains and hemangiomas. J Am Acad Dermatol. 2008;58(2):261-85.
138. Batta K, Goodyear HM, Moss C, et al. Randomised controlled study of early pulsed dye laser treatment of uncomplicated childhood haemangiomas: results of a 1-year analysis. Lancet. 2002;360(9332):521-7.
139. David LR, Malek MM, Argenta LC. Efficacy of pulse dye laser therapy for the treatment of ulcerated haemangiomas: a review of 78 patients. Br J Plast Surg. 2003;56(4):317-27.
140. Witman PM, Wagner AM, Scherer K, et al. Complications following pulsed dye laser treatment of superficial hemangiomas. Lasers Surg Med. 2006;38(2):116-23.
141. McHeik JN, Renauld V, Duport G, et al. Surgical treatment of haemangioma in infants. Br J Plast Surg. 2005;58(8):1067-72.
142. Drolet BA, Frommelt PC, Chamlin SL, et al. Approach to initiation and use of propranolol for infantile hemangioma: report of a consensus conference. Pediatrics. Epub 2012 Dec 24.